Some questions need a clinician

This site gives no medical advice

Desert Peptides is a reading guide. It doesn't assess symptoms, review medical histories or decide whether a medicine fits someone. It offers no appointments or prescriptions.

There is no contact form here. This page doesn't provide a way to send health records or get a medical reply. Personal care needs a licensed clinician who can ask questions about your situation.

Questions about a care service

For questions about a Promise Peptides account, consultation or prescription, contact that service through its own support channels. Desert Peptides can't view those records or answer for the service. The home page has its MOTS-c care link.

If you're considering a visit, useful questions include why the treatment is being proposed and what human evidence supports it. What remains unknown, and how would follow-up work? A clinician may decline a request after reviewing it.

Online care still depends on location

A website being visible in your state doesn't settle whether care is available there. HHS explains how care across state lines works, including licensing and registration routes. The patient's location matters.

Availability can depend on both state and treatment. This guide doesn't keep an eligibility list, and an article can't confirm your access. That needs checking with the service or clinician involved.

It's a useful detail to establish early in a conversation. Otherwise, a broad claim about U.S. availability can sound like an answer about you. Those aren't quite the same question.

A prescription leaves evidence questions open

FDA's explanation of compounded-drug risks says these medicines aren't FDA-approved. FDA hasn't reviewed them for safety, effectiveness and quality before marketing in the way it reviews approved drugs. Prescription review is a different process.

For MOTS-c, there are no published human treatment studies. Human studies have measured natural levels, while treatment findings come from cells and animals. A consultation doesn't turn those results into proven benefits for people.

Retatrutide remains investigational, with no approved prescription product. The comparison puts these differences together. A care link for one peptide doesn't answer an access question about another.

Checking something you read here

The link beside a finding is a good place to start. Look for who took part and what changed. The reading list explains which question each source helps answer.

The questions page also covers common mix-ups, including prescribed versus FDA-approved. It's fine if reading leaves you with a question to take into a visit. Understanding a claim doesn't require acting on it.